Goldman Sachs
SION icon

Goldman Sachs’s Sionna Therapeutics SION Stock Holding History

Goldman Sachs’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Buy
388,810
+125,636
+48% +$5.03M ﹤0.01% 2798
2026
Q1 		$10.6M Buy
263,174
+226,905
+626% +$8.66M ﹤0.01% 3032
2025
Q4 		$1.49M Buy
36,269
+24,091
+198% +$914K ﹤0.01% 4837
2025
Q3 		$358K Sell
12,178
-33,870
-74% -$737K ﹤0.01% 5675
2025
Q2 		$799K Sell
46,048
-17,693
-28% -$232K ﹤0.01% 4857
2025
Q1 		$667K Buy
+63,741
New +$1.04M ﹤0.01% 4997

Other funds holding SION

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TPG GP A
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Atlas Venture Life Science Advisors
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Enavate Sciences
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Goldman Sachs's SION Position: Q2 2026 in Review

Goldman Sachs increased its Sionna Therapeutics (SION) stake by 48% in Q2 2026, buying an estimated $5.03M and bringing the position to 388,810 shares worth $17.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2798.

Goldman Sachs first reported a position in SION in Q1 2025 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Goldman Sachs held 388,810 shares of Sionna Therapeutics worth $17.1M as of Q2 2026.
  • Goldman Sachs bought 125,636 Sionna Therapeutics shares in Q2 2026, an estimated $5.03M.
  • Sionna Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2798 holding.
  • Goldman Sachs first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.